The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Addressing disparities in access to CAR-T therapy for hematological malignancies
Nausheen Ahmed, MD, University of Kansas Medical Center, Kansas City, MO, comments on the socioeconomic and ethnic disparities relating to access to CAR-T therapy and participation in CAR-T clinical trials in patients with hematological malignancies. Dr Ahmed sheds light on the underrepresentation of ethnic minorities from rural communities in clinical trials and the impact of socioeconomic factors and location on access to CAR-T therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite: consulting, BMS: advisory board
